Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

Completed · Phase 2 · Has a placebo group

Conditions studied: Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis

In brief

This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG ≥12 mmHg as determined by the central reader assigned to this study). Upon successful screening, subjects will be randomized to receive either emricasan 50 mg BID, 25 mg BID, or 5 mg BID or matching placebo BID.

Key facts

Study ID

NCT02960204

Run by

Histogen

People needed

263

Starts

2016-10-17

Expected to finish

2019-04-08

Last updated by the study team

2022-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subjects 18 years or older, able to provide written informed consent and able to understand and willing to comply with the requirements of the study.
• Cirrhosis due to NASH with exclusion of other causes of cirrhosis (e.g. chronic viral hepatitis, alcoholic liver disease, etc.)
• Compensated cirrhosis OR Decompensated cirrhosis with no more than 1 prior significant decompensating event
• Severe portal hypertension defined as HVPG ≥12 mmHg
• Subjects who are on NSBB, nitrates, diuretics, lactulose, rifaximin, or statins must be on a stable dose for at least 3 months prior to Day 1
• Willingness to utilize effective contraception (for both males and females of childbearing potential) from Screening to 4 weeks after the last dose of study drug

You may not qualify if…

• Evidence of severe decompensation
• Severe hepatic impairment defined as a Child-Pugh score ≥10
• ALT (alanine transaminase) > 3 times upper limit of normal (ULN) or AST (aspartate transaminase) >5 times ULN during screening
• Estimated creatinine clearance <30 mL/min
• Prior transjugular intrahepatic portosystemic shunt or other porto-systemic bypass procedure
• Known portal vein thrombosis
• Symptoms of biliary colic, e.g. due to symptomatic gallstones, within the last 6 months, unless resolved following cholecystectomy
• Current use of medications that are considered inhibitors of OATP1B1 and OATP1B3 transporters
• Alpha-fetoprotein >50 ng/mL
• History or presence of clinically concerning cardiac arrhythmias, or prolongation of screening (pre-treatment) QTcF interval of >500 msec
• History of or active malignancies, other than those successfully treated with curative intent and believed to be cured
• Prior liver transplant
• Change in diabetes medications or vitamin E within 3 months of screening
• Uncontrolled diabetes mellitus (HbA1c >9%) within 3 months of screening
• Significant systemic or major illness other than liver disease
• HIV infection
• Use of controlled substances (including inhaled or injected drugs) or non-prescribed use of prescription drugs within 1 year of screening
• If female: planned or known pregnancy, positive urine or serum pregnancy test, or lactating/breastfeeding
• Previous treatment with emricasan or active investigational medication (except methacetin) in a clinical trial within 3 months prior to Day 1

Where it is running

• Pasadena — Pasadena, California, United States
• Rialto — Rialto, California, United States
• Palmetto Bay — Palmetto Bay, Florida, United States
• Atlanta — Atlanta, Georgia, United States
• Clive — Clive, Iowa, United States
• Baltimore — Baltimore, Maryland, United States
• Detroit — Detroit, Michigan, United States
• Rochester — Rochester, Minnesota, United States
• Saint Paul — Saint Paul, Minnesota, United States
• Kansas City — Kansas City, Missouri, United States
• Durham — Durham, North Carolina, United States
• Philadelphia — Philadelphia, Pennsylvania, United States
• Philadelphia — Philadelphia, Pennsylvania, United States
• Germantown — Germantown, Tennessee, United States
• Arlington — Arlington, Texas, United States
• Houston — Houston, Texas, United States
• San Antonio — San Antonio, Texas, United States
• San Antonio — San Antonio, Texas, United States
• Norfolk — Norfolk, Virginia, United States
• Richmond — Richmond, Virginia, United States
• Richmond — Richmond, Virginia, United States
• Seattle, Washington — Seattle, Washington, United States
• Bonn — Bonn, Germany
• Halle (Saale) — Halle, Germany
• Leipzig — Leipzig, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.